A RANDOMIZED, CONTROLLED CLINICAL TRIAL ON PIPERACILLIN/TAZOBACTAM VERSUS TICARCILLIN/CLAVULANIC ACID FOR THE TREATMENT OF BACTERIAL INFECTIONS

A randomized, open-label, controlled study was conducted for the treatment on 124 hospitalized patients with lower respiratory tract infection and urinary tract infections to compare the efficacy and safety of two β-lactamase inhibitor combinations, piperacillin-tazobactam and ticarcillin-clavulanic aicd .63 patients received piperacillin-tazobactam(4g·(500mg)-1) every 8 hours by intravenous infusion and 61 patients received ticarcillin/clavulanic acid(3g·(200mg)-1) every 8 hours by intravenous infusion. The duration was 7-14 days in two groups. 63 of 79 cases received piperacillin/tazobactam and 61 of 84 cases received ticarcillin/clavulanic acid were assessable for clinical efficacy. The overall effcacy rates were 90.5% for the piperacillin/tazobactam group and 88.5% for the ticarcillin /clavulanic acid group, whereas the bacterial eradication rates were 90.2% and 92.0%, respectively. 78 (77.2%) of 101 strains isolated from patients produced β-lactamase.The adverse drug reaction was evaluated in 65 cases of piperacillin/tazobactam group and 62 cases of ticarcillin/clavulanic acid group, the adverse drug reaction rates were 7.69%(5/65) and 8.06%(5/62), respectively. The results showed that there were no statistical differences between these two groups.(P0.05) .